Oppenheimer

Late Thursday, Tandem Diabetes Care Inc (NASDAQ: TNDM) announced FDA approval of its t:slim X2 insulin pump with Basal-IQ for Type 1 diabetes patients, which is planned for an August launch. With the company’s balance sheet position recently improved, investors will likely shift their...

Red Hat Inc (NYSE: RHT) stock tanked more than 12 percent Friday after the company’s first-quarter earnings report failed to wow the market. Red Hat also announced a $1 billion buyback. A number of analysts have weighed in on Red Hat stock following the report. Here’s a sampling of...

Data service and self-service analytics company Alteryx Inc (NYSE: AYX) is likely to benefit from the increasing quest for data, according to Oppenheimer.  The Analyst Analyst Ittai Kidron initiated coverage of Alteryx with an Outperform and 12-18-month price target of $48. The Thesis Alteryx...

Shares of Tesla Inc (NASDAQ: TSLA) aren't far off their all-time highs, but the stock remains one of the most divisive on Wall Street. Oppenheimer looked at five battleground points for bulls and bears in a Tuesday report.  The Analyst Oppenheimer's Colin Rusch maintains...

ArQule, Inc. (NASDAQ: ARQL) shares are up 367 percent year-over-year, but they’re still undervalued, according to Oppenheimer. The Rating Analyst Hartaj Singh initiated coverage on ArQule with an Outperform rating and $7 price target. The Thesis Oppenheimer expects the ARQ 092/751 and ARQ...

Axovant Sciences Ltd (NASDAQ: AXON) announced Wednesday that it licensed global rights to Oxford BioMedica’s investigational gene therapy for Parkinson’s Disease. As some experts see it, the drug could be a game changer. The Rating Oppenheimer analysts Jay Olson and Silvan Tuerkcan...

Shares of VistaGen Therapeutics Inc (NASDAQ: VTGN) rocketed up over 40 percent to $1.36 in after-hours trading on Thursday — a mere fraction of the 500 percent upside implied by a late-day note from Oppenheimer. The Analyst Oppenheimer’s Jay Olson initiated coverage on VistaGen with...

Darden Restaurants, Inc. (NYSE: DRI) has underperformed its peers significantly this year, but its low valuation has set the table for over 20 percent of upside, according to Oppenheimer. The Analyst Oppenheimer analyst Brian Bittner reiterated an Outperform rating and $105 price target on Darden...

Oppenheimer's prior case against being aggressive on Ulta Beauty Inc (NASDAQ: ULTA) stock was based on concerns of a slowdown in the beauty segment -- an assumption that no longer holds true. The Analyst Oppenheimer's Rupesh Parikh upgraded Ulta Beauty from Perform to Outperform with a...

Trade Desk Inc (NASDAQ: TTD) is a provider of a cloud-based platform for managing digital ad campaigns that boasts a "unique" SaaS asset that positions the company well for future share gains, according to Oppenheimer. The Analyst Oppenheimer's Brian Schwartz initiated coverage of...